ORION CORPORATION PRESS RELEASE 8 JANUARY 2026 at 12.00 EET Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in ...

As these systems evolve, I believe therapeutic ultrasound is poised to become medicine's next general-purpose platform.

The FDA and European Medicines Agency (EMA) have awarded orphan drug designation to CPI-008 (cRGD-ZW800-1), a novel ...

A full-body scan every few years, for some, is a small price to pay for a wide-ranging check-up. Is it the right choice for ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

"Expanded CEUS training will help prepare the next generation of sonographers to deliver safer, more effective and more patient-centered care," according to Maria Stanczak, a mmber of the ICUS board ...

Around 10 percent of the U.S. adult population — over 25 million Americans — experience some form of tinnitus.

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Ottimo Pharma Limited ("Ottimo"), an innovative, ...

Jasmine, a Bradenton teenager, has been recovering for weeks after what the hospital describes as life-saving surgery.

Though most nosebleeds are mild and benign, they shouldn’t happen. Experts weigh in on when to see a doctor ...

Frequent health examinations and screening for people who discovers the symptoms on the early state, which helps to prevent ...

By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...